Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin

Jason C. Hall, Laura A. Marlow, Adam C. Mathias, Louis K. Dawson, William F. Durham, Kenneth A. Meshaw, Robert J. Mullin, Aidan J. Synnott, Daniel L. Small, Murli Krishna, Daniel Hoff, Julia Schüler, Steven Hart, Fergus J Couch, Gerardo Colon-Otero, John A III Copland

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for 3) from PACC liver metastasis were implanted into athymic nude mice. Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno-histochemical (IHC) biomarkers were used to confirm that the PDTX model represents human PACC. The antitumor activities of multiple drugs (5-FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and imatinib) were tested. Tumor size was measured over 74 days or until they reached an endpoint volume of ~800 mm3. Tests to measure serum lipase levels and histological analyses of tumor tissues were also conducted to assess PACC progression and re-differentiation. Results: The model presented here expresses the same IHC markers found in human PACC. In the chemotherapy study, oxaliplatin produced a prolonged durable growth response associated with increased apoptosis, decreased serum lipase levels and increased healthy acinar cells. Bevacizumab also produced a significant growth response, but the effect was not prolonged as demonstrated by oxaliplatin treatment. The other chemotherapies had moderate to little effect, particularly after treatment ceased. Mutations in DNA repair genes are common in PACC and increase tumor susceptibility to oxaliplatin. To explore this we performed IHC and found no nuclear expression of BRCA2 in our model, indicating a mutation affecting nuclear localization. Gene sequencing confirms BRCA2 has a homozygous gene deletion on Exon 10, which frequently causes a protein truncation. Conclusions: In summary, we report the development and characterization of the first and only preclinical PACC PDTX model. Here we show sustained anti-tumor activity of single agent oxaliplatin, a compound that is more effective in tumors that harbor mutations in DNA repair genes. Our data shows that BRCA2 is mutated in our PACC model, which could contribute to the oxaliplatin sensitivity observed. Further studies on this rare PACC model can serve to elucidate other novel therapies, biomarkers, and molecular mechanisms of signaling and drug resistance.

Original languageEnglish (US)
Article number129
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
StatePublished - May 10 2016

Fingerprint

oxaliplatin
Acinar Cell Carcinoma
Heterografts
Tumors
Cells
Genes
irinotecan
Chemotherapy
Biomarkers
gemcitabine
Lipase
Neoplasms
Repair
Nude Mice
DNA Repair
Mutation
DNA
Ports and harbors
Fluorouracil
Pharmaceutical Preparations

Keywords

  • BRCA2
  • Chemotherapy
  • Individualized medicine
  • Oxaliplatin
  • Pancreatic acinar cell carcinoma
  • Patient derived tumor xenograft
  • Precision medicine
  • Tumor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. / Hall, Jason C.; Marlow, Laura A.; Mathias, Adam C.; Dawson, Louis K.; Durham, William F.; Meshaw, Kenneth A.; Mullin, Robert J.; Synnott, Aidan J.; Small, Daniel L.; Krishna, Murli; Hoff, Daniel; Schüler, Julia; Hart, Steven; Couch, Fergus J; Colon-Otero, Gerardo; Copland, John A III.

In: Journal of Translational Medicine, Vol. 14, No. 1, 129, 10.05.2016.

Research output: Contribution to journalArticle

Hall, JC, Marlow, LA, Mathias, AC, Dawson, LK, Durham, WF, Meshaw, KA, Mullin, RJ, Synnott, AJ, Small, DL, Krishna, M, Hoff, D, Schüler, J, Hart, S, Couch, FJ, Colon-Otero, G & Copland, JAIII 2016, 'Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin', Journal of Translational Medicine, vol. 14, no. 1, 129. https://doi.org/10.1186/s12967-016-0875-z
Hall, Jason C. ; Marlow, Laura A. ; Mathias, Adam C. ; Dawson, Louis K. ; Durham, William F. ; Meshaw, Kenneth A. ; Mullin, Robert J. ; Synnott, Aidan J. ; Small, Daniel L. ; Krishna, Murli ; Hoff, Daniel ; Schüler, Julia ; Hart, Steven ; Couch, Fergus J ; Colon-Otero, Gerardo ; Copland, John A III. / Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. In: Journal of Translational Medicine. 2016 ; Vol. 14, No. 1.
@article{d78d49ab72ed4245ac9c6e3d3790bd0e,
title = "Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin",
abstract = "Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for 3) from PACC liver metastasis were implanted into athymic nude mice. Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno-histochemical (IHC) biomarkers were used to confirm that the PDTX model represents human PACC. The antitumor activities of multiple drugs (5-FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and imatinib) were tested. Tumor size was measured over 74 days or until they reached an endpoint volume of ~800 mm3. Tests to measure serum lipase levels and histological analyses of tumor tissues were also conducted to assess PACC progression and re-differentiation. Results: The model presented here expresses the same IHC markers found in human PACC. In the chemotherapy study, oxaliplatin produced a prolonged durable growth response associated with increased apoptosis, decreased serum lipase levels and increased healthy acinar cells. Bevacizumab also produced a significant growth response, but the effect was not prolonged as demonstrated by oxaliplatin treatment. The other chemotherapies had moderate to little effect, particularly after treatment ceased. Mutations in DNA repair genes are common in PACC and increase tumor susceptibility to oxaliplatin. To explore this we performed IHC and found no nuclear expression of BRCA2 in our model, indicating a mutation affecting nuclear localization. Gene sequencing confirms BRCA2 has a homozygous gene deletion on Exon 10, which frequently causes a protein truncation. Conclusions: In summary, we report the development and characterization of the first and only preclinical PACC PDTX model. Here we show sustained anti-tumor activity of single agent oxaliplatin, a compound that is more effective in tumors that harbor mutations in DNA repair genes. Our data shows that BRCA2 is mutated in our PACC model, which could contribute to the oxaliplatin sensitivity observed. Further studies on this rare PACC model can serve to elucidate other novel therapies, biomarkers, and molecular mechanisms of signaling and drug resistance.",
keywords = "BRCA2, Chemotherapy, Individualized medicine, Oxaliplatin, Pancreatic acinar cell carcinoma, Patient derived tumor xenograft, Precision medicine, Tumor",
author = "Hall, {Jason C.} and Marlow, {Laura A.} and Mathias, {Adam C.} and Dawson, {Louis K.} and Durham, {William F.} and Meshaw, {Kenneth A.} and Mullin, {Robert J.} and Synnott, {Aidan J.} and Small, {Daniel L.} and Murli Krishna and Daniel Hoff and Julia Sch{\"u}ler and Steven Hart and Couch, {Fergus J} and Gerardo Colon-Otero and Copland, {John A III}",
year = "2016",
month = "5",
day = "10",
doi = "10.1186/s12967-016-0875-z",
language = "English (US)",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin

AU - Hall, Jason C.

AU - Marlow, Laura A.

AU - Mathias, Adam C.

AU - Dawson, Louis K.

AU - Durham, William F.

AU - Meshaw, Kenneth A.

AU - Mullin, Robert J.

AU - Synnott, Aidan J.

AU - Small, Daniel L.

AU - Krishna, Murli

AU - Hoff, Daniel

AU - Schüler, Julia

AU - Hart, Steven

AU - Couch, Fergus J

AU - Colon-Otero, Gerardo

AU - Copland, John A III

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for 3) from PACC liver metastasis were implanted into athymic nude mice. Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno-histochemical (IHC) biomarkers were used to confirm that the PDTX model represents human PACC. The antitumor activities of multiple drugs (5-FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and imatinib) were tested. Tumor size was measured over 74 days or until they reached an endpoint volume of ~800 mm3. Tests to measure serum lipase levels and histological analyses of tumor tissues were also conducted to assess PACC progression and re-differentiation. Results: The model presented here expresses the same IHC markers found in human PACC. In the chemotherapy study, oxaliplatin produced a prolonged durable growth response associated with increased apoptosis, decreased serum lipase levels and increased healthy acinar cells. Bevacizumab also produced a significant growth response, but the effect was not prolonged as demonstrated by oxaliplatin treatment. The other chemotherapies had moderate to little effect, particularly after treatment ceased. Mutations in DNA repair genes are common in PACC and increase tumor susceptibility to oxaliplatin. To explore this we performed IHC and found no nuclear expression of BRCA2 in our model, indicating a mutation affecting nuclear localization. Gene sequencing confirms BRCA2 has a homozygous gene deletion on Exon 10, which frequently causes a protein truncation. Conclusions: In summary, we report the development and characterization of the first and only preclinical PACC PDTX model. Here we show sustained anti-tumor activity of single agent oxaliplatin, a compound that is more effective in tumors that harbor mutations in DNA repair genes. Our data shows that BRCA2 is mutated in our PACC model, which could contribute to the oxaliplatin sensitivity observed. Further studies on this rare PACC model can serve to elucidate other novel therapies, biomarkers, and molecular mechanisms of signaling and drug resistance.

AB - Background: Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, accounting for 3) from PACC liver metastasis were implanted into athymic nude mice. Tumors were grown and passaged from the host mice into new mice to be tested for therapeutic response. Immuno-histochemical (IHC) biomarkers were used to confirm that the PDTX model represents human PACC. The antitumor activities of multiple drugs (5-FU, irinotecan, oxaliplatin, gemcitabine, bevacizumab, erlotinib, doxorubicin and imatinib) were tested. Tumor size was measured over 74 days or until they reached an endpoint volume of ~800 mm3. Tests to measure serum lipase levels and histological analyses of tumor tissues were also conducted to assess PACC progression and re-differentiation. Results: The model presented here expresses the same IHC markers found in human PACC. In the chemotherapy study, oxaliplatin produced a prolonged durable growth response associated with increased apoptosis, decreased serum lipase levels and increased healthy acinar cells. Bevacizumab also produced a significant growth response, but the effect was not prolonged as demonstrated by oxaliplatin treatment. The other chemotherapies had moderate to little effect, particularly after treatment ceased. Mutations in DNA repair genes are common in PACC and increase tumor susceptibility to oxaliplatin. To explore this we performed IHC and found no nuclear expression of BRCA2 in our model, indicating a mutation affecting nuclear localization. Gene sequencing confirms BRCA2 has a homozygous gene deletion on Exon 10, which frequently causes a protein truncation. Conclusions: In summary, we report the development and characterization of the first and only preclinical PACC PDTX model. Here we show sustained anti-tumor activity of single agent oxaliplatin, a compound that is more effective in tumors that harbor mutations in DNA repair genes. Our data shows that BRCA2 is mutated in our PACC model, which could contribute to the oxaliplatin sensitivity observed. Further studies on this rare PACC model can serve to elucidate other novel therapies, biomarkers, and molecular mechanisms of signaling and drug resistance.

KW - BRCA2

KW - Chemotherapy

KW - Individualized medicine

KW - Oxaliplatin

KW - Pancreatic acinar cell carcinoma

KW - Patient derived tumor xenograft

KW - Precision medicine

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84969174895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969174895&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0875-z

DO - 10.1186/s12967-016-0875-z

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 129

ER -